Search results
Results from the WOW.Com Content Network
Roche had paid $1.9 billion for New-York based Flatiron Health in 2018 to speed its development of cancer medicines and support its efforts to price them based on how well they work. The ...
In February 2018, Roche announced it would acquire Flatiron Health, a business specialising in US cancer data analytics, for $1.9 billion. [57] [58] In June of the same year the company announced it would acquire the outstanding shares of Foundation Medicine for $2.4 billion ($137 per share). [59]
The Flatiron Institute is an American internal research division of the Simons Foundation, launched in 2016. [1] The mission of the Flatiron Institute is to advance scientific research through computational methods, including data analysis, theory, modeling, and simulation. The Flatiron Institute was dedicated with a ceremony on September 6, 2017.
Bill Maris (born William J. Maris) is an American entrepreneur and venture capitalist focused on technology and the life sciences. Bill Maris's investments have to date resulted in over 150 exits and more than 50 companies that have grown to over $1B in value, including: Nest (acquired by Google), Uber (NASDAQ: UBER), Crowdstrike (NASDAQ: CRWD), Coinbase (NASDAQ: COIN), 23andme, Flatiron ...
"I never understood that," Amy Nelms, the owner of the private studio Flatiron Pilates, whose clients include Lily Allen, Emma Corrin, and Jodie Comer, says when asked why people think of pilates ...
First edition (publ. Flatiron Books) How Not to Die: Discover the Foods Scientifically Proven to Prevent and Reverse Disease is a book by Michael Greger, M.D. with Gene Stone, published in 2015 that argues for the health benefits of a whole food plant-based diet. [1] The book was a New York Times Best Seller. [2]
Visitors to New York City’s famed Flatiron Building may have noticed the landmark’s lesser-known neighbor — a narrow high-rise that would be modest if not for its extravagant gold dome. Now ...
Fidanacogene elaparvovec, previously known by its study ID number SPK-9001, [12] is a gene therapy for the treatment of hemophilia B.It was developed by Spark in partnership with Pfizer.